Mould DR - Search Results

1

The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development.

Mould DR, Sweeney KR. Mould DR, et al. Curr Opin Drug Discov Devel. 2007 Jan;10(1):84-96. Curr Opin Drug Discov Devel. 2007. PMID: 17265746 Review.

2

Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary.

Turner D, Griffiths AM, Wilson D, Mould DR, Baldassano RN, Russell RK, Dubinsky M, Heyman MB, de Ridder L, Hyams J, Martin de Carpi J, Conklin L, Faubion WA, Koletzko S, Bousvaros A, Ruemmele FM. Turner D, et al. Among authors: mould dr. Gut. 2020 Jan;69(1):32-41. doi: 10.1136/gutjnl-2018-317987. Epub 2019 Apr 12. Gut. 2020. PMID: 30979718 Free article.

3

Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors.

Mould DR, Holford NH, Schellens JH, Beijnen JH, Hutson PR, Rosing H, ten Bokkel Huinink WW, Rowinsky EK, Schiller JH, Russo M, Ross G. Mould DR, et al. Clin Pharmacol Ther. 2002 May;71(5):334-48. doi: 10.1067/mcp.2002.123553. Clin Pharmacol Ther. 2002. PMID: 12011819

4

Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients.

Mould DR, Zhang X, Nieforth K, Salgo M, Buss N, Patel IH. Mould DR, et al. Clin Pharmacol Ther. 2005 Jun;77(6):515-28. doi: 10.1016/j.clpt.2005.02.005. Clin Pharmacol Ther. 2005. PMID: 15961983

5

Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study.

Mould DR, Fleming GF, Darcy KM, Spriggs D. Mould DR, et al. Br J Clin Pharmacol. 2006 Jul;62(1):56-70. doi: 10.1111/j.1365-2125.2006.02718.x. Br J Clin Pharmacol. 2006. PMID: 16842379 Free PMC article. Clinical Trial.

6

Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response.

Mould DR, Baumann A, Kuhlmann J, Keating MJ, Weitman S, Hillmen P, Brettman LR, Reif S, Bonate PL. Mould DR, et al. Br J Clin Pharmacol. 2007 Sep;64(3):278-91. doi: 10.1111/j.1365-2125.2007.02914.x. Epub 2007 May 16. Br J Clin Pharmacol. 2007. PMID: 17506867 Free PMC article. Clinical Trial.

7

Using disease progression models as a tool to detect drug effect.

Mould DR, Denman NG, Duffull S. Mould DR, et al. Clin Pharmacol Ther. 2007 Jul;82(1):81-6. doi: 10.1038/sj.clpt.6100228. Epub 2007 May 16. Clin Pharmacol Ther. 2007. PMID: 17507925

8

A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.

Mould DR, Sweeney K, Duffull SB, Neylon E, Hamlin P, Horwitz S, Sirotnak F, Fleisher M, Saunders ME, O'Connor OA. Mould DR, et al. Clin Pharmacol Ther. 2009 Aug;86(2):190-6. doi: 10.1038/clpt.2009.80. Epub 2009 May 27. Clin Pharmacol Ther. 2009. PMID: 19474785

9

Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development.

Mould DR, Green B. Mould DR, et al. BioDrugs. 2010 Feb 1;24(1):23-39. doi: 10.2165/11530560-000000000-00000. BioDrugs. 2010. PMID: 20055530 Review.

10

Population pharmacokinetic-pharmacodynamic modeling of biological agents: when modeling meets reality.

Mould DR, Frame B. Mould DR, et al. J Clin Pharmacol. 2010 Sep;50(9 Suppl):91S-100S. doi: 10.1177/0091270010376965. J Clin Pharmacol. 2010. PMID: 20881222

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results